Jpmorgan Chase & CO Mersana Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MRSN
# of Institutions
121Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$48 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$29.9 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$28.1 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$21.5 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$20.8 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $241M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...